Search

Merck & Co Inc.

Closed

SectorHealthcare

149.57 2.01

Overview

Share price change

24h

Current

Min

145.81

Max

147.35

Key metrics

By Trading Economics

Income

2.9B

-1.3B

Sales

321M

17B

P/E

Sector Avg

115.88

56.432

EPS

-0.13

Dividend yield

2.31

Profit margin

-8.051

Employees

73,000

EBITDA

3.4B

1.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.22% upside

Dividends

By Acuity

Dividend yield

Sector Avg

2.31%

2.27%

Next Earnings

29 paź 2026

Next Dividend date

7 paź 2026

Next Ex Dividend date

14 gru 2026

Market Stats

By TradingEconomics

Market Cap

50B

357B

Previous open

147.56

Previous close

149.57

News Sentiment

By Acuity

33%

67%

43 / 339 Ranking in Healthcare

Merck & Co Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 wrz 2026, 23:06 UTC

Merck & Co Inc declined in after-market trading, moving from a small gain to a modest loss and remaining below its 20-day moving average.

17 wrz 2026, 20:07 UTC

News

Merck's shares are advancing following positive Phase 3 trial results for its collaboration with Moderna on a personalized mRNA cancer therapy for melanoma.

16 wrz 2026, 23:51 UTC

Merck & Co Inc is advancing in after-market trading, supported by positive U.S. retail sales data, despite ongoing concerns over TIC flows and Treasury yields.

15 wrz 2026, 23:01 UTC

Merck & Co Inc shares are lower in after-market hours. Broader market sentiment is impacted by a significant decline in the New York Empire State Manufacturing Index.

14 wrz 2026, 23:06 UTC

Merck & Co Inc shares rose in after-market trading following Monday's close, despite earlier declines and no specific news to explain the movement.

11 wrz 2026, 19:36 UTC

Merck & Co Inc shares are declining amid broader market trends following inflation data that heightened interest rate hike speculation. No specific company news was identified.

10 wrz 2026, 20:07 UTC

News

Merck & Co Inc shares are lower today despite HSBC raising its price target to $172 and noting insider buying activity.

9 wrz 2026, 19:36 UTC

News

Merck & Co. shares are lower after a court upheld Medicare's drug-price negotiations, raising concerns about future prescription drug spending.

8 wrz 2026, 23:06 UTC

News

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

4 wrz 2026, 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

3 wrz 2026, 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2 wrz 2026, 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

1 wrz 2026, 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

31 sie 2026, 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

28 sie 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27 sie 2026, 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26 sie 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 sie 2026, 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24 sie 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21 sie 2026, 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20 sie 2026, 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19 sie 2026, 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17 sie 2026, 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15 sie 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14 sie 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13 sie 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12 sie 2026, 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11 sie 2026, 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10 sie 2026, 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 sie 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

9.22% upside

12 Months Forecast

Average 160.405 USD  9.22%

High 180 USD

Low 105 USD

Based on 19 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

14

Buy

5

Hold

0

Sell

Sentiment

By Acuity

43 / 339 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.